Production of recombinant glycoprotein C from Equid alphaherpesvirus 1 and evaluation of the immune response induced in mice
DOI:
https://doi.org/10.24215/15142590e053Keywords:
Equid alfaherpesvirus 1, glycoprotein C, immune response, BALB/c miceAbstract
Equid alfaherpesvirus 1 (EHV-1) causes respiratory disease, abortions, perinatal death and neurological disorders in horses. Envelope glycoproteins are the most immunodominant antigens that generate an immune response in infected animals. Natural infection and available vaccines provide partial and short-term protection against reinfection. In this study, EHV-1 glycoprotein C was expressed with a recombinant baculovirus and the ability to induce protective immunity in BALB / c mice when challenged with the virus was analyzed. Different routes of administration and adjuvants were evaluated. Glycoprotein C induced a specific IgG response in serum, however, it failed to prevent the entry of the virus into the lung or the appearance of clinical signs, which were variable among different groups of mice. In all immunized groups the entry of the virus into the lung only was delayed. When adjuvants were used, the viral titer was significantly lower than in the control group, as well as in the intranasally immunized group. Therefore, the glycoprotein C induced partial protection against the challenge with the virus depending on the adjuvant and the route of immunization used.
Downloads
Metrics
References
Allen GP, Bryans JT. Molecular epizootiology, pathogenesis and prophylaxis of equine herpesvirus -1 infections. En: Pandey R.1986. Progress in Veterinary Microbiology and Immunology. Basilea, Karger, pp.78-144.
Allen GP. 2006. Antemortem detection of latent infection with neuropathogenic strains of equine herpesvirus-1 in horses. American Journal of Veterinary Research. 67(8):1401-5. https://doi.org/10.2460/ajvr.67.8.1401
American Association of Equine Practitioners (AAEP). 2020. Equine Herpesvirus (Rhinopneumonitis); Vaccination guidelines. [En línea] Disponible en: https://aaep.org/guidelines/vaccination-guidelines/risk-based-vaccination-guidelines/equine-herpesvirus-rhinopneumonitis [Consultado 20/7/2020].
Barnett PV, Pullen L, Williams L, Doel TR. 1996. International Bank for foot-and-mouth disease vaccine: assessment of Montanide ISA 25 and ISA 206, two commercially available oil adjuvants. Vaccine. 14(13): 1187-98.https://doi.org/10.1016/s0264-410x(96)00055-2
Crowther JR. 2009. The ELISA Guidebook. 2º Ed. Vienna, Austria. Humana Press.
Cunningham HC. 1971. Virología Práctica. Zaragoza, España, Editorial Acribia.
Kydd JH, Townsend HGG, Hannant D. 2006. The equine immune response to equine herpesvirus-1: The virus and its vaccines. Veterinary Immunology and Immunopathology. 111(1-2):15-30.https://doi.org/10.1016/j.vetimm.2006.01.005
Foote CE, Love DN, Gilkerson JR, Rota J, Trevor-Jones P, Ruitenberg KM, Wellington JE, Whalley JM. 2005. Serum antibody responses to equine herpesvirus 1 glycoprotein D in horses, pregnant mares and young foals. Veterinary Immunology and Immunopathology. 105(1-2):47-57. https://doi.org/10.1016/j.vetimm.2004.12.012
Foote CE, Raidal SL, Pecenpetelovska G, Wellington JE, Whalley JM. 2006. Inoculation of mares and very young foals with EHV-1 glycoproteins D and B reduces virus shedding following respiratory challenge with EHV-1. Veterinary Immunology and Immunopathology. 111(1-2):97-108. https://doi.org/10.1016/j.vetimm.2006.01.012
Fuentealba NA. 2012. Herpesvirus equino 1: estudio de la expresión de proteínas antigénicas y evaluación de la respuesta inmune inducida. Tesis de doctorado en Ciencias Veterinarias, Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata.
Fuentealba NA, Sguazza GH, Zanuzzi CN, Bravi ME, Scrochi MR, Valera AR, Corva SG, Gimeno EJ, Pecoraro MR, Galosi CM. 2019. Immunoprotective response induced by recombinant glycoprotein D in the BALB/c respiratory mouse model of Equid alphaherpesvirus 1 infection. Revista Argentina de Microbiología. 51(2):119-29. https://doi.org/10.1016/j.ram.2018.05.004
Galosi CM, Barbeito CG, Vila Roza MV, Cid de la Paz V, Ayala MA, Corva SG, Etcheverrigaray ME, Gimeno EJ. 2004. Argentine strain of equine herpesvirus 1 isolated from an aborted foetus shows slow virulence in mouse respiratory and abortion models. Veterinary Microbiology. 103(1-2):1-12. https://doi.org/10.1016/j.vetmic.2004.07.015
Ganne V, Eloit M, Laval A, Adam M, Trouve G. 1994. Enhancement of the efficacy of a replication-defective adenovirus-vectored vaccine by the addition of oil adjuvants. Vaccine. 12:1190-6. https://doi.org/10.1016/0264-410x(94)90242-9
Guo PX, Goebel S, Perkus ME, Taylor J, Norton E, Allen G, Languet B, Desmettre P, Paoletti E. 1990. Coexpression by vaccinia virus recombinants of equine herpesvirus 1 glycoproteins gp13 and gp14 results in potentiated immunity. Journal of Virology. 64(5):2399-406. https://doi.org/ 10.1128/JVI.64.5.2399-2406.1990.
Huemer HP, Nowotny N, Crabb BS, Meyer H, Hübert PH. 1995. gp13 (EHV-gC): a complement receptor induced by equine herpesviruses. Virus Research. 37(2):113-26. https://doi.org/10.1016/0168-1702(95)00027-n
Lunn DP, Davis-Poynter N, Flaminio MJ, Horohov DW, Osterrieder K, Pusterla N, Townsend HG. 2009. Equine herpesvirus-1 consensus statement. Journal of Veterinary Internal Medicine. 23(3):450-61. https://doi.org/10.1111/j.1939-1676.2009.0304.x
Ma G, Azab W, Osterrieder N. 2013. Equine herpesviruses type 1 (EHV-1) and 4 (EHV-4) masters of co-evolution and a constant threat to equids and beyond. Veterinary Microbiology. 167(1-2):123-34. https://doi.org/10.1016/j.vetmic.2013.06.018
Minke JM, Audonnet JC, Fischer L. 2004. Equine viral vaccines: the past, present and future. Veterinary Research. 35(4):425-43.https://doi.org/10.1051/vetres:2004019
Osterrieder N, Wagner R, Brandmüller C, Schmidt P, Wolf H, Kaaden OR. 1995. Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB). Virology. 208(2):500-10. https://doi.org/10.1006/viro.1995.1181
Osterrieder N. 1999. Construction and characterization of an equine herpesvirus 1 glycoprotein C negative mutant. Virus Research. 59:165-77. https://doi.org/10.1016/s0168-1702(98)00134-8
Packiarajah P, Walker C, Gilkerson J, Whalley JM, Love DN. 1998. Immune responses and protective efficacy of recombinant baculovirus-expressed glycoproteins of equine herpesvirus 1 (EHV-1) gB, gC and gD alone or in combinations in BALB/c mice. Veterinary Microbiology. 61(4):261-78. https://doi.org/10.1016/s0378-1135(98)00189-8
Ruitenberg KM, Walker C, Wellington JE, Love DN, Whalley JM. 1999. ADN-mediated immunization with glycoprotein D of equine herpesvirus 1 (EHV-1) in a murine model of EHV-1 respiratory infection. Vaccine. 17(3):237-44. https://doi.org/10.1016/S0264-410X(98)00192-3
Stills HF. 2005. Adjuvants and antibody production: dispelling the myths associated with Freund’s complete and other adjuvants. ILAR Journal. 46(3):280-93. https://doi.org/10.1093/ilar.46.3.280
Stokes A, Alber DG, Cameron RS, Marshall RN, Allen GP, Killington RA. 1996. The production of a truncated form of baculovirus expressed EHV-1 glycoprotein C and its role in protection of C3H (H-2Kk) mice against virus challenge. Virus Research. 44(2): 97-109. https://doi.org/10.1016/0168-1702(96)01339-1
Tewari D, Nair SV, De Ungria MC, Lawrence GL, Hayden M, Love DN, Field HJ, Whalley JM. 1995. Immunization with glycoprotein C of equine herpesvirus-1 is associated with accelerated virus clearance in a murine model. Archives of Virology. 140(4):789-97. https://doi.org/10.1007/BF01309967
Tewari D, Whalley JM, Love DN, Field HJ. 1994. Characterization of immune responses to baculovirus expressed equine herpesvirus type 1 glycoproteins D and H in a murine model. Journal of General Virology. 75(Pt 7):1735-41. https://doi.org/10.1099/0022-1317-75-7-1735
Vandekerckhove A, Glorieux S, Gryspeerdt AC, Steukers L,Duchateau L, Osterrieder N, Van de Walle GR, Nauwynck HJ. 2010. Replication kinetics of neurovirulent versus non-neurovirulent equine herpesvirus type 1 strains in equine nasal mucosal explants. The Journal of General Virology. 91(Pt 8):2019-28. https://doi.org/10.1099/vir.0.019257-0
Wagner B, Goodman LB, Babasyan S, Freer H, Torsteinsdót-tir S, Svansson V, Björnsdóttir S, Perkin GA. 2015. Antibody and cellular immune responses of naïve mares to repeated vaccination with an inactivated equine herpesvirus vaccine. Vaccine.33(42):5588-97. https://doi.org/10.1016/j.vaccine.2015.09.009
Whalley JM, Love DN. 2002. Improved vaccine strategies for management of equine herpesvirus. Report of Rural Industries Research and Development Corporation, Sydney. Disponible en https://www.agrifutures.com.au/wp-content/uploads/publications/02-111.pdf [Consultado 10/3/2020]
Weerasinghe CU, Learmonth GS, Gilkerson JR, Foote CE,Wellington JE, Whalley JM. 2006. Equine herpesvirus 1 glycoprotein D expressed in E. coli provides partial protection against equine herpesvirus infection in mice and elicits virus-neutralizing antibodies in the horse. Veterinary Immunology and Immunopathology. 111(1-2):59-66. https://doi.org/10.1016/j.vetimm.2006.01.009
Zanuzzi C, Scrochi M, Fuentealba N, Nishida F, Portiansky E, Muglia C, Gimeno E, Barbeito C, Galosi C. 2014. Effects of equid herpesvirus 1 (EHV-1) AR8 and HH1 strains on BALB-c mice. Archives of Virology. 159(1):141-5. https://doi.org/10.1007/s00705-013-1782-8
Zanuzzi CN, Bravi ME, Scrochi MR, Nishida F, Fuentealba NA, Diessler ME, Sguazza HG, Muglia CI, Gimeno EJ, Portiansky EL, Barbeito CG, Galosi CM. 2016. Microvascular lesions and changes in cell proliferation and death, and cytokine expression in the placentas of mice experimentally infected with equid herpesvirus 1. Research in Veterinary Science. 109:121-8. https://doi.org/10.1016/j.rvsc.2016.09.005
Zhang Y, Smith PM, Tarbet EB, Osterrieder N, Jennings SR, O'Callaghan DJ. 1998. Protective immunity against equine herpesvirus type-1(EHV-1) infection in mice induced by recombinant EHV-1 gD. Virus Research. 56(1):11-24. https://doi.org/10.1016/S0168-1702(98)00054-9
Zhang Y, Smith PM, Jennings SR, O’Callaghan DJ. 2000. Quantitation of virus-specific classes of antibodies following immunization of mice with attenuated equine herpesvirus 1 and viral glycoprotein D. Virology. 268(2):482-92. https://doi.org/10.1006/viro.2000.0197
Published
How to Cite
Issue
Section
License
Authors retain the copyright and assign to the journal the right of the first publication, with the with the terms of the Creative Commons attribution license. This type of license allows other people to download the work and share it, as long as credit is granted for the authorship, but does not allow them to be changed in any way or used them commercially.
Analecta Veterinaria by School of Veterinary Sciences, National University of La Plata is distributed under a Creative Commons Attribution-NonCommercial-NoDeriv 4.0 International License.